Parexel International Corp (PRXL) 50.15 $PRXL
PAREXEL Appoints Peter Steiger, Ph.D., As Vice President Of Medical Imaging In Its Technology Subsidiary
PR Newswire - Mon Apr 14, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the appointment of Peter Steiger, Ph.D., to the newly created position of Vice President and Chief Scientific Officer for Medical Imaging. Dr. Steiger, who has more than 25 years of experience in the application of specialized medical imaging techniques in support of biopharmaceutical product development, will oversee the worldwide medical imaging scientific strategy at PAREXEL Informatics. PAREXEL Informatics provides advanced technology solutions to facilitate the clinical development process.
Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
PAREXEL International elects two SVPs of Clinical Research Services
M2 - Mon Apr 07, 9:33AM CDT
Biopharmaceutical company PAREXEL International (NasdaqGS
RXL) revealed on Monday the addition of Roland Andersson PhD, and Thomas Senderovitz MD, as senior vice presidents of its Clinical Research Services (CRS) strategic business unit.
Uptrend Call Working As Parexel International Stock Rises 12.1% (PRXL)
Comtex SmarTrend(R) - Mon Apr 07, 9:21AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ RXL) on December 24th, 2013 at $44.68. In approximately 3 months, Parexel International has returned 12.08% as of today's recent price of $50.07.
PAREXEL Strengthens Executive Leadership With Appointments Of Roland Andersson, Ph.D. And Thomas Senderovitz, M.D. As Senior Vice Presidents Of Clinical Research Services
PR Newswire - Mon Apr 07, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced Dr. Roland Andersson, Ph.D., and Dr. Thomas Senderovitz, M.D., as Senior Vice Presidents in the Company's Clinical Research Services (CRS) strategic business unit. The executives will be centrally involved in developing and implementing PAREXEL's global corporate objectives.
PAREXEL Announces Date of Third Quarter Fiscal Year 2014 Earnings Release and Conference Call
GlobeNewswire - Tue Apr 01, 8:30AM CDT
PAREXEL International Corporation (Nasdaq RXL) will release financial results for the Third Quarter of Fiscal Year 2014 on Tuesday, April 29, 2014 after the close of the stock market. The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PRNewswire website at www.prnewswire.com.
Strategic Partnerships Perceived As Most Effective Biopharmaceutical Outsourcing Model In Meeting Key Sponsor Needs, PAREXEL Report Reveals
PR Newswire Europe - Mon Mar 31, 5:01AM CDT
-- More than half of biopharmaceutical companies surveyed use a Strategic Partnership model
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Mar 25, 9:05AM CDT
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quintiles Transnational Holdings Inc. (NYSE: Q), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on Q, PKI, PRXL and CRL can be downloaded upon signing up at:
23.5% Return Seen to Date on SmarTrend Parexel International Call (PRXL)
Comtex SmarTrend(R) - Fri Mar 21, 11:07AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ RXL) on December 24th, 2013 at $44.68. In approximately 3 months, Parexel International has returned 23.51% as of today's recent price of $55.18.
PAREXEL Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 2:20PM CDT
PAREXEL has delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 14.83%.
PAREXEL Expands Regional Distribution Center And Supply Depot Network To Enhance Global Clinical Logistics Services
PR Newswire Europe - Wed Mar 19, 5:01AM CDT
- Increases global capacity and adds new secondary packaging and labeling services to more efficiently deliver clinical trial supplies
Charles River Acquires CRO Division of Galapagos - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:40PM CDT
In a move to advance its position in the fast-growing outsourced discovery services market, Charles River Laboratories entered into a definitive agreement to acquire the CRO services division of Galapagos NV.
Parexel International Shares Up 26.0% Since SmarTrend's Buy Recommendation (PRXL)
Comtex SmarTrend(R) - Fri Mar 14, 9:41AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ RXL) on December 24th, 2013 at $44.67. In approximately 3 months, Parexel International has returned 25.98% as of today's recent price of $56.28.
Charles River Aims To Be 'One-Stop Shop' With Buyout
at Investor's Business Daily - Thu Mar 13, 10:39AM CDT
Contract research organization Charles River Laboratories (CRL) said Thursday that it's agreed to buy the CRO business of Belgian drugmaker Galapagos NV. Charles River stock touched a more than five-year high in early trading on the stock market...
Shares of PRXL Up 24.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 07, 9:17AM CST
SmarTrend identified an Uptrend for Parexel International (NASDAQ RXL) on December 24th, 2013 at $44.68. In approximately 2 months, Parexel International has returned 24.52% as of today's recent price of $55.63.
PAREXEL Appoints Peter Steiger, Ph.D., As Vice President Of Medical Imaging In Its Technology Subsidiary
PR Newswire - Mon Apr 14, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the appointment of Peter Steiger, Ph.D., to the newly created position of Vice President and Chief Scientific Officer for Medical Imaging. Dr. Steiger, who has more than 25 years of experience in the application of specialized medical imaging techniques in support of biopharmaceutical product development, will oversee the worldwide medical imaging scientific strategy at PAREXEL Informatics. PAREXEL Informatics provides advanced technology solutions to facilitate the clinical development process.
Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
PAREXEL International elects two SVPs of Clinical Research Services
M2 - Mon Apr 07, 9:33AM CDT
Biopharmaceutical company PAREXEL International (NasdaqGS
RXL) revealed on Monday the addition of Roland Andersson PhD, and Thomas Senderovitz MD, as senior vice presidents of its Clinical Research Services (CRS) strategic business unit. Uptrend Call Working As Parexel International Stock Rises 12.1% (PRXL)
Comtex SmarTrend(R) - Mon Apr 07, 9:21AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ
RXL) on December 24th, 2013 at $44.68. In approximately 3 months, Parexel International has returned 12.08% as of today's recent price of $50.07. PAREXEL Strengthens Executive Leadership With Appointments Of Roland Andersson, Ph.D. And Thomas Senderovitz, M.D. As Senior Vice Presidents Of Clinical Research Services
PR Newswire - Mon Apr 07, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced Dr. Roland Andersson, Ph.D., and Dr. Thomas Senderovitz, M.D., as Senior Vice Presidents in the Company's Clinical Research Services (CRS) strategic business unit. The executives will be centrally involved in developing and implementing PAREXEL's global corporate objectives.
PAREXEL Announces Date of Third Quarter Fiscal Year 2014 Earnings Release and Conference Call
GlobeNewswire - Tue Apr 01, 8:30AM CDT
PAREXEL International Corporation (Nasdaq
RXL) will release financial results for the Third Quarter of Fiscal Year 2014 on Tuesday, April 29, 2014 after the close of the stock market. The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PRNewswire website at www.prnewswire.com. Strategic Partnerships Perceived As Most Effective Biopharmaceutical Outsourcing Model In Meeting Key Sponsor Needs, PAREXEL Report Reveals
PR Newswire Europe - Mon Mar 31, 5:01AM CDT
-- More than half of biopharmaceutical companies surveyed use a Strategic Partnership model
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Mar 25, 9:05AM CDT
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quintiles Transnational Holdings Inc. (NYSE: Q), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on Q, PKI, PRXL and CRL can be downloaded upon signing up at:
23.5% Return Seen to Date on SmarTrend Parexel International Call (PRXL)
Comtex SmarTrend(R) - Fri Mar 21, 11:07AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ
RXL) on December 24th, 2013 at $44.68. In approximately 3 months, Parexel International has returned 23.51% as of today's recent price of $55.18. PAREXEL Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 2:20PM CDT
PAREXEL has delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 14.83%.
PAREXEL Expands Regional Distribution Center And Supply Depot Network To Enhance Global Clinical Logistics Services
PR Newswire Europe - Wed Mar 19, 5:01AM CDT
- Increases global capacity and adds new secondary packaging and labeling services to more efficiently deliver clinical trial supplies
Charles River Acquires CRO Division of Galapagos - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:40PM CDT
In a move to advance its position in the fast-growing outsourced discovery services market, Charles River Laboratories entered into a definitive agreement to acquire the CRO services division of Galapagos NV.
Parexel International Shares Up 26.0% Since SmarTrend's Buy Recommendation (PRXL)
Comtex SmarTrend(R) - Fri Mar 14, 9:41AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ
RXL) on December 24th, 2013 at $44.67. In approximately 3 months, Parexel International has returned 25.98% as of today's recent price of $56.28. Charles River Aims To Be 'One-Stop Shop' With Buyout
at Investor's Business Daily - Thu Mar 13, 10:39AM CDT
Contract research organization Charles River Laboratories (CRL) said Thursday that it's agreed to buy the CRO business of Belgian drugmaker Galapagos NV. Charles River stock touched a more than five-year high in early trading on the stock market...
Shares of PRXL Up 24.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 07, 9:17AM CST
SmarTrend identified an Uptrend for Parexel International (NASDAQ
RXL) on December 24th, 2013 at $44.68. In approximately 2 months, Parexel International has returned 24.52% as of today's recent price of $55.63. 
